Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
20/05/2026 19:52
May 21 (Reuters) - Maat Pharma SA MAAT.PA: MAAT PHARMA PROVIDES AN UPDATE ON THE APPLICATION FOR MARKETING AUTHORIZATION OF MAAT013 (XERVYTEG®) IN THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE MAAT PHARMA SA - RECEIVES 'NEGATIVE TREND' OPINION FOR UPCOMING JUNE CHMP VOTE MAAT PHARMA SA - TO REQUEST RE-EXAMINATION OF MAAT013 APPLICATION AFTER JUNE CHMP VOTE MAAT PHARMA SA - EXTENDS FINANCIAL VISIBILITY INTO NOVEMBER 2026 Source text: ID:nBw9x1mfBa Further company coverage: MAAT.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026